MEG, Author at TissueCypher®

About MEG

This author has not yet filled in any details.
So far MEG has created 67 blog entries.

Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019

PITTSBURGH, May 08, 2019 (GLOBE NEWSWIRE) — Cernostics, developer of next-genera Read More

Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019MEG2022-05-10T16:37:09+00:00

Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics

– US and EU patents for TissueCypher® cover methods for detecting risk of
progression to esophageal cance Read More

Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical DiagnosticsMEG2022-05-10T16:38:09+00:00

Cernostics Raises $2.5 Million in Series A1 Financing, Led by Illumina Ventures

– TissueCypher® Barrett’s Esophagus Assay is First Precision Medicine Platform for Prevention of Esophageal Read More

Cernostics Raises $2.5 Million in Series A1 Financing, Led by Illumina VenturesMEG2022-05-10T16:39:22+00:00

Cernostics Announces Leadership Team Expansion

– New Commercial Leader Positions Company for Continued Success and Growth –

BETHLEHEM Read More

Cernostics Announces Leadership Team ExpansionMEG2022-05-10T16:40:24+00:00

American College of Gastroenterology

Read More

American College of GastroenterologyMEG2020-09-08T18:40:25+00:00

Digestive Disease Week

Read More

Digestive Disease WeekMEG2020-09-08T18:40:17+00:00

JP Morgan Healthcare Conference

Read More

JP Morgan Healthcare ConferenceMEG2020-09-08T18:40:13+00:00

New TissueCypher® Validation Study Identifies High Risk Barrett’s Esophagus Patients Who are 46x More Likely to Have Cancer at Time of Biopsy

Study indicates that TissueCypher^® may detect a field effect associated with high grade dysplasia and can Read More

New TissueCypher® Validation Study Identifies High Risk Barrett’s Esophagus Patients Who are 46x More Likely to Have Cancer at Time of BiopsyMEG2022-05-10T16:41:58+00:00

Individualized risk prediction in Barrett’s esophagus

Barrett’s esophagus (BE), which is a precursor to esophageal adenocarcinoma (EAC), is an increasing healthcare challenge Read More

Individualized risk prediction in Barrett’s esophagusMEG2020-09-08T18:35:16+00:00

UPMC Partners with Cernostics to Pursue ‘Precision Medicine’

PITTSBURGH, PA – As part of its wide-ranging efforts to better target treatments t Read More

UPMC Partners with Cernostics to Pursue ‘Precision Medicine’MEG2022-05-09T16:36:21+00:00